α-Glucosidase-IN-119
α-Glucosidase-IN-119 is an α-glucosidase inhibitor with an IC50 of 3.32 μM and oral effectiveness. α-Glucosidase-IN-119 acts as an antihyperglycemic agent, reduces blood glucose levels, restores normal levels of alkaline phosphatase, aspartate transaminase, alanine transaminase, urea, blood urea nitrogen, and total protein, and exhibits antioxidant activity. α-Glucosidase-IN-119 can be used for the research of type 2 diabetes mellitus.
For research use only. We do not sell to patients.
- Formula: C27H19N5O5S
- Molecular Weight:525.54
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
α‑glucosidase 3.32 μM (IC50) |
α-Glucosidase-IN-119 (Compound 10e) (1-250 μM; 10 min) potently inhibits α-glucosidase with an IC50 of 3.32 μM, and its activity is 21.05-fold higher than that of Acarbose (HY-B0089)[1].
α-Glucosidase-IN-119 (31.25-1000 μg/mL; 30 min) induces dose-dependent hemolysis of red blood cells, with hemolysis rates ranging from 1.34% to 11.54% within the tested concentration range[1].
α-Glucosidase-IN-119 (31.25-1000 μg/mL) exhibits moderate DPPH free radical scavenging activity, with an IC50 value of 105.68 μg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (male, 8-10 weeks old, 150-180 g, streptozotocin-induced type 2 diabetes)[1]
-
Dosage:10 mg/kg; 50 mg/kg
-
Administration:p.o.; 21 days
-
Result:Significantly reduced fasting blood glucose levels compared to the diabetic control group (p < 0.001) by day 14, with further improvement by day 21.
Significantly blunted post-prandial blood glucose rises and reduced the area under the glucose curve compared to the diabetic control group (p < 0.001).
Significantly reduced serum total cholesterol and triglyceride levels compared to the diabetic control group (p < 0.001).
Significantly reduced serum aspartate transaminase (AST) and alanine transaminase (ALT) levels, and restored total protein levels to near-normal compared to the diabetic control group (p < 0.001).
Significantly reduced blood urea nitrogen (BUN), serum creatinine, and serum urea levels compared to the diabetic control group (p < 0.001).
Restored hepatic architecture (reduced sinusoid dilation, inflammation), renal architecture (reduced glomerular constriction, tubular necrosis), and pancreatic islet structure (increased β-cell population, restored cell boundaries) compared to the diabetic control group.
Chemical Information
-
Molecular Weight 525.54
-
Formula C27H19N5O5S
-
SMILES
O=C(/C(S1)=C/C2=CN(C3=CC=CC=C3)N=C2C4=CC=CC([N+]([O-])=O)=C4)N(CC(NC5=CC=CC=C5)=O)C1=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
α-Glucosidase-IN-119 Related Classifications
HY-184701 Related Classifications
Powered by Bioz